A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Discover why private ingrown hairs pose more than cosmetic concerns, including infection risks, and learn 6 effective solutions from dermatologists.

Tasman District Council imposed the classification after receiving a report in August last year that Boy had attacked another ...

Eventual Australian Survivor: All Stars winner David Genat didn’t have an easy run to landing the title of Sole Survivor. The ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The wave of melioidosis infections has been exacerbated by poverty and the increasing severity of storms and floods resulting ...

Aspiration of the abscess might be necessary in some cases. The need for open surgical drainage has decreased, however, since the success of percutaneous drainage. Surgery should be reserved for ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...